Avoid overhydration in patients at risk of cardiac failure. Severe jaw, muscle or joint pain. Patients who develop osteonecrosis of the jaw while on therapy. HCM patients w/ >1 course of retreatment. Hydrate patient appropriately prior to treatment. Maintain urinary output of 2 L daily throughout therapy; good oral hygiene & have a dental exam w/ preventive prior to treatment. Monitor patient for hypercalcemia-related metabolic parameters including serum conc of Ca, phosphate, Mg & creatinine prior to each administration & throughout treatment; renal function before treatment & withhold for renal deterioration. Investigate patients having hypercalcemia associated w/ malignancy after post-treatment evaluation at least 7 days after drug initiation. Short-term supplemental therapy if hypocalcemia, hypophosphatemia or hypomagnesemia occur. Not to be mixed or diluted w/ Ca-containing soln or other Ca-containing drug or product. Concomitant use w/ bisphosphonates, nephrotoxic drugs or shorter than recommended duration of IV infusion. Not recommended in severe renal impairment w/ CrCl <30 mL/min. Pregnancy. Lactating woman should not breastfeed during & after treatment. Not indicated for use in childn.
Sign Out
